Breaking News, Collaborations & Alliances

Duality Biologics, BioNTech Expand ADC Alliance

To develop, manufacture and commercialize a third ADC candidate DB-1305 globally.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Duality Biologics (Suzhou) Co. Ltd., a clinical-stage biotech company focused on next generation antibody-drug conjugate therapeutics to treat cancer and autoimmune diseases, has expanded  its collaboration with BioNTech SE to develop, manufacture and commercialize a third ADC candidate DB-1305 globally, excluding Mainland China, Hong Kong and Macau Special Administrative Regions. DB-1305 is currently in a Phase 1/2 clinical trial (NCT05438329) for solid tumors.    Under the agreements, Dualit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters